CORCYM Company Profile

Background

Overview

CORCYM is a global medical device company specializing in surgical solutions for structural heart disease. Established in June 2021 following the acquisition of LivaNova PLC's heart valve business by Gyrus Capital, CORCYM inherited a legacy of over 50 years in cardiac surgery innovation. The company is headquartered in London, United Kingdom, and operates manufacturing and R&D facilities in Saluggia, Italy, and Burnaby, Canada. With a workforce of approximately 850 employees, CORCYM serves over 100 countries worldwide.

Mission and Vision

CORCYM's mission is to assist heart surgeons in providing optimal care to patients by offering advanced surgical solutions for structural heart disease. The company's vision is to become a leading entity dedicated to heart surgeons and their patients, delivering the best solutions to combat structural heart disease.

Industry Significance

As a specialized medical device manufacturer, CORCYM plays a crucial role in the cardiovascular sector, particularly in the development and production of heart valves and related surgical instruments. The company's products are CE and FDA certified and approved in major markets, including Japan and China, underscoring its global reach and industry significance.

Key Strategic Focus

Core Objectives

CORCYM aims to leverage its expertise in mechanical valves and build its growth engine with leading product platforms such as Perceval® and Memo, while investing in research and development to pursue new products and partnerships.

Areas of Specialization

The company specializes in the development, manufacturing, and marketing of mechanical and tissue heart valves, annuloplasty rings, and surgical accessories for treating heart valve disease. Notable products include the Perceval sutureless aortic valve, the MEMO 4D semi-rigid mitral ring, and the HAART aortic annuloplasty devices.

Key Technologies Utilized

CORCYM employs advanced technologies in its product offerings, including sutureless valve designs and minimally invasive surgical instruments, to enhance surgical outcomes and patient recovery times.

Primary Markets Targeted

The company targets global markets, with a significant presence in Europe, North America, Asia, and emerging markets, aiming to address the needs of heart surgeons and patients worldwide.

Financials and Funding

Funding History

CORCYM was acquired by Gyrus Capital, a Swiss private equity firm, on December 3, 2020. The company operates as a privately held entity, and specific details regarding total funds raised or recent funding rounds are not publicly disclosed.

Notable Investors

Gyrus Capital is the primary investor in CORCYM, providing the necessary capital for the company's operations and growth initiatives.

Utilization of Capital

The capital is utilized to support CORCYM's operations, research and development activities, and global expansion efforts, ensuring the continuous delivery of innovative surgical solutions for structural heart disease.

Pipeline Development

Key Pipeline Candidates

CORCYM's product pipeline includes:

Perceval Plus: An advanced sutureless aortic valve designed for minimally invasive procedures.

Memo 4D: A semi-rigid mitral annuloplasty ring aimed at improving mitral valve repair outcomes.

HAART: An aortic annuloplasty device intended to enhance aortic valve repair procedures.

Stages of Development

These products are in various stages of development, with some already available in the market and others undergoing clinical evaluations.

Target Conditions

The pipeline focuses on treating structural heart diseases, including aortic and mitral valve conditions.

Anticipated Milestones

CORCYM continues to invest in research and development to advance its product offerings and expand its market presence. Specific timelines for upcoming milestones are not publicly disclosed.

Technological Platform and Innovation

Proprietary Technologies

CORCYM's proprietary technologies include sutureless valve designs and minimally invasive surgical instruments, which aim to improve surgical efficiency and patient outcomes.

Significant Scientific Methods

The company employs advanced surgical techniques, including robotic-assisted procedures, to enhance the precision and safety of heart valve surgeries. In August 2025, CORCYM's Perceval Plus sutureless aortic valve was used in a robotic aortic valve replacement at the Cleveland Clinic, marking a significant advancement in minimally invasive cardiac surgery.

Leadership Team

Executive Profiles

Christian Mazzi: Chief Executive Officer. Prior to joining CORCYM, Mazzi was an operating partner at Evolve Healthcare Partners and held leadership roles at Mundipharma and Bain & Company.

Piero Vecchi: Chief Financial Officer. Vecchi has over 25 years of experience in finance within the medical device industry, previously serving as Vice President Corporate Controller at LivaNova and Corporate Controller at Sorin Group.

Mara Chiaro: Chief Transformation Officer. Chiaro has more than 15 years of experience in the heart valve business, having held various roles in clinical, quality, and regulatory affairs, and was previously responsible for scientific communication at LivaNova.

Prof. Borut Gersak: Chief Medical Officer. Gersak is a Professor of Surgery at the University of Ljubljana and has extensive experience in cardiovascular surgery, including minimally invasive and robotic vascular surgery.

Eric Hardeman: Head of Partner Markets. Hardeman manages distributor markets across various regions and has a background in commercial roles at Allergan and LivaNova.

Rodolphe Morand: Head of Direct Markets. Morand oversees direct markets in Europe, North America, Japan, Australia, and New Zealand, with experience in vascular surgery and endovascular activities.

Fabio Tagliaretti: Chief Operating Officer. Tagliaretti has over 30 years of experience in operations, regulatory affairs, quality, R&D, and supply chain, having worked globally for multinational companies like ABB, Philips, and Hitachi Energy.

Competitor Profile

Market Insights and Dynamics

The global market for structural heart disease devices is experiencing growth due to an aging population and increasing prevalence of heart valve diseases. Technological advancements, such as minimally invasive procedures and robotic-assisted surgeries, are driving innovation and competition in this sector.

Competitor Analysis

Key competitors in the structural heart disease device market include:

Edwards Lifesciences: A leading company specializing in heart valve technologies and critical care monitoring.

Medtronic: A global medical device company offering a range of cardiovascular products, including heart valves and surgical instruments.

Boston Scientific: Provides a variety of medical devices, including those for structural heart interventions.

Strategic Collaborations and Partnerships

CORCYM collaborates with leading professionals in heart surgery to develop clinical studies and investigator-initiated research activities, aiming to advance heart valve technologies.

Operational Insights

CORCYM's focus on innovative surgical solutions, such as sutureless valves and minimally invasive instruments, positions it competitively in the market. The company's global presence and commitment to research and development further strengthen its market position.

Strategic Opportunities and Future Directions

CORCYM plans to leverage its foundations in mechanical valves and build its growth engine with leading product platforms like Perceval® and Memo, while investing in research and development to pursue new products and partnerships. The company aims to expand its market presence and continue delivering innovative solutions for structural heart disease.